Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin

References

• Burningham Z, Hashibe M, Spector L, et al. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2(1):14.
   PubMedGoogle Scholar
• Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist. 2002;7(4):348–359.
   PubMed Web of Science ®Google Scholar
• Raber I, Asnani A. Cardioprotection in cancer therapy: novel insights with anthracyclines. Cardiovasc Res. 2019;115(5):915–921.
   PubMed Web of Science ®Google Scholar
• Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112:980–984.
   Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801.
   PubMed Web of Science ®Google Scholar
• Fornaro A, Olivotto I, Rigacci L, et al. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single Centre experience. Eur J Heart Fail. 2018;20(5):898–906.
   PubMed Web of Science ®Google Scholar
• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:063–093.
   Web of Science ®Google Scholar
• Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89(5):942–949.
   PubMed Web of Science ®Google Scholar
• Russell RR, Alexander J, Jain D, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23(4):856–884.
   PubMed Web of Science ®Google Scholar
• Jensen MM, Haase C, Zerahn B. Interstudy repeatability of left and right ventricular volume estimations by serial-gated tomographic radionuclide angiographies using a cadmium-zinc-telluride detector gamma camera. Clin Physiol Funct Imaging. 2015;35(6):418–424.
   PubMed Web of Science ®Google Scholar
• Dresdale A, Bonow RO, Wesley R, et al. Prospective evaluation of doxorubicin‐induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer. 1983;52(1):51–60.
   PubMed Web of Science ®Google Scholar
• Shantakumar S, Olsen M, Vo TT, et al. Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol. 2016;8:53–59.
   PubMed Web of Science ®Google Scholar
• Haarmark C, Haase C, Jensen MM, et al. Pre-chemotherapy values for left and right ventricular volumes and ejection fraction by gated tomographic radionuclide angiography using a cadmium-zinc-telluride detector gamma camera. J Nucl Cardiol. 2016;23(1):87–97.
   PubMed Web of Science ®Google Scholar
• Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer addressing the unresolved issues. Circulation. 2012;126(23):2749–2763.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988.
   PubMed Web of Science ®Google Scholar
• Bloom MW, Hamo CE, Cardinale D, et al. Cancer therapy–related cardiac dysfunction and heart failure. Circ Hear Fail. 2016;9:e002661.
   PubMed Web of Science ®Google Scholar
• Kamphuis JAM, Linschoten M, Cramer MJ, et al. Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy. Cardiooncology. 2020;6:23.
   PubMedGoogle Scholar
• Pedersen S, Larsen KO, Christensen AH, et al. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta Oncol. 2022;61(1):45–51.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–220.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Moussa E, Zamzam M, Kamel A, et al. Corrigendum to “Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma” [J. Egypt Natl. Cancer Instit. 29 (2017) 53–56]. J Egypt Natl Canc Inst. 2017;29(2):119.
   PubMedGoogle Scholar
• Doherty GJ, Davidson D, Wong HH, et al. Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma. Anticancer Drugs. 2019;30(1):110–115.
   PubMed Web of Science ®Google Scholar
• Teske AJ, Linschoten M, Kamphuis JAM, et al. Cardio-oncology: an overview on outpatient management and future developments. Neth Heart J. 2018;26(11):521–532.
   PubMed Web of Science ®Google Scholar
• Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6‐hour infusion regimen. A prospective randomized evaluation. Cancer. 1990;65(4):870–873.
   PubMed Web of Science ®Google Scholar
• Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109–1118.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines. J Am Heart Assoc. 2020;9:e018403.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;2011:CD003917.
   Google Scholar
• Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013;49(13):2900–2909.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318–1332.
   PubMed Web of Science ®Google Scholar
• Schwartz CL, Wexler LH, Krailo MD, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63(1):54–61.
   PubMed Web of Science ®Google Scholar
• Tap WD, Wagner AJ, Schöffski P, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA. 2020;323(13):1266–1276.
   PubMed Web of Science ®Google Scholar
• Jones RL, Wagner AJ, Kawai A, et al. Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft-tissue sarcoma treated in the ANNOUNCE phase III randomized trial. Clin Cancer Res. 2021;27(14):3861–3866.
   PubMed Web of Science ®Google Scholar
• Appel JM, Nielsen D, Zerahn B, et al. Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol. 2007;46(5):576–580.
   PubMed Web of Science ®Google Scholar
• Kotwinski P, Smith G, Cooper J, et al. Body surface area and baseline blood pressure predict subclinical anthracycline cardiotoxicity in women treated for early breast cancer. PLoS One. 2016;11(12):e0165262.
   PubMed Web of Science ®Google Scholar